175 related articles for article (PubMed ID: 23308129)
1. BMI1, stem cell factor acting as novel serum-biomarker for Caucasian and African-American prostate cancer.
Siddique HR; Parray A; Zhong W; Karnes RJ; Bergstralh EJ; Koochekpour S; Rhim JS; Konety BR; Saleem M
PLoS One; 2013; 8(1):e52993. PubMed ID: 23308129
[TBL] [Abstract][Full Text] [Related]
2.
Ganaie AA; Beigh FH; Astone M; Ferrari MG; Maqbool R; Umbreen S; Parray AS; Siddique HR; Hussain T; Murugan P; Morrissey C; Koochekpour S; Deng Y; Konety BR; Hoeppner LH; Saleem M
Clin Cancer Res; 2018 Dec; 24(24):6421-6432. PubMed ID: 30087142
[TBL] [Abstract][Full Text] [Related]
3. Comparison of prostate secretory protein with prostate specific antigen and prostatic acid phosphatase as a serum biomarker for diagnosis and monitoring patients with prostate carcinoma.
Huang CL; Brassil D; Rozzell M; Schellhammer PF; Wright GL
Prostate; 1993; 23(3):201-12. PubMed ID: 7694265
[TBL] [Abstract][Full Text] [Related]
4. ROBO1, a tumor suppressor and critical molecular barrier for localized tumor cells to acquire invasive phenotype: study in African-American and Caucasian prostate cancer models.
Parray A; Siddique HR; Kuriger JK; Mishra SK; Rhim JS; Nelson HH; Aburatani H; Konety BR; Koochekpour S; Saleem M
Int J Cancer; 2014 Dec; 135(11):2493-506. PubMed ID: 24752651
[TBL] [Abstract][Full Text] [Related]
5. Polycomb-group oncogenes EZH2, BMI1, and RING1 are overexpressed in prostate cancer with adverse pathologic and clinical features.
van Leenders GJ; Dukers D; Hessels D; van den Kieboom SW; Hulsbergen CA; Witjes JA; Otte AP; Meijer CJ; Raaphorst FM
Eur Urol; 2007 Aug; 52(2):455-63. PubMed ID: 17134822
[TBL] [Abstract][Full Text] [Related]
6. African-American men with prostate cancer have larger tumor volume than Caucasian men despite no difference in serum prostate specific antigen.
Fuletra JG; Kamenko A; Ramsey F; Eun DD; Reese AC
Can J Urol; 2018 Feb; 25(1):9193-9198. PubMed ID: 29524974
[TBL] [Abstract][Full Text] [Related]
7. Using Serological Proteome Analysis to Identify Serum Anti-Nucleophosmin 1 Autoantibody as a Potential Biomarker in European-American and African-American Patients With Prostate Cancer.
Dai L; Li J; Xing M; Sanchez TW; Casiano CA; Zhang JY
Prostate; 2016 Nov; 76(15):1375-86. PubMed ID: 27418398
[TBL] [Abstract][Full Text] [Related]
8. Prostate-specific antigen (PSA) and PSA density: racial differences in men without prostate cancer.
Henderson RJ; Eastham JA; Culkin DJ; Kattan MW; Whatley T; Mata J; Venable D; Sartor O
J Natl Cancer Inst; 1997 Jan; 89(2):134-8. PubMed ID: 8998182
[TBL] [Abstract][Full Text] [Related]
9. [Improved discrimination between prostatic carcinoma and benign prostatic hyperplasia by determination of free prostate-specific antigen percentage].
Wolff JM; Borchers H; Boeckmann W; Habib FK; Jakse G
Urologe A; 1997 May; 36(3):255-8. PubMed ID: 9265347
[TBL] [Abstract][Full Text] [Related]
10. BMI1 polycomb group protein acts as a master switch for growth and death of tumor cells: regulates TCF4-transcriptional factor-induced BCL2 signaling.
Siddique HR; Parray A; Tarapore RS; Wang L; Mukhtar H; Karnes RJ; Deng Y; Konety BR; Saleem M
PLoS One; 2013; 8(5):e60664. PubMed ID: 23671559
[TBL] [Abstract][Full Text] [Related]
11. Prostate-specific antigen concentration in young men: new estimates and review of the literature.
Sutcliffe S; Pakpahan R; Sokoll LJ; Elliott DJ; Nevin RL; Cersovsky SB; Walsh PC; Platz EA
BJU Int; 2012 Dec; 110(11):1627-35. PubMed ID: 22502603
[TBL] [Abstract][Full Text] [Related]
12. Serum-to-urinary prostate-specific antigen ratio in patients with benign prostatic hyperplasia and prostate cancer.
Hillenbrand M; Bastian M; Steiner M; Zingler C; Müller M; Wolff JM; Seiter H; Schuff-Werner P
Anticancer Res; 2000; 20(6D):4995-6. PubMed ID: 11326656
[TBL] [Abstract][Full Text] [Related]
13. Serum proteomic profiling can discriminate prostate cancer from benign prostates in men with total prostate specific antigen levels between 2.5 and 15.0 ng/ml.
Ornstein DK; Rayford W; Fusaro VA; Conrads TP; Ross SJ; Hitt BA; Wiggins WW; Veenstra TD; Liotta LA; Petricoin EF
J Urol; 2004 Oct; 172(4 Pt 1):1302-5. PubMed ID: 15371828
[TBL] [Abstract][Full Text] [Related]
14. Comparison of clinical and pathological features in African-American and Caucasian patients with localized prostate cancer.
Kang JS; Maygarden SJ; Mohler JL; Pruthi RS
BJU Int; 2004 Jun; 93(9):1207-10. PubMed ID: 15180606
[TBL] [Abstract][Full Text] [Related]
15. Association of Prostate-Specific Antigen Velocity With Clinical Progression Among African American and Non-Hispanic White Men Treated for Low-Risk Prostate Cancer With Active Surveillance.
Nelson TJ; Javier-DesLoges J; Deka R; Courtney PT; Nalawade V; Mell L; Murphy J; Parsons JK; Rose BS
JAMA Netw Open; 2021 May; 4(5):e219452. PubMed ID: 33999164
[TBL] [Abstract][Full Text] [Related]
16. Potential effect of anti-inflammatory drug use on PSA kinetics and subsequent prostate cancer diagnosis: Risk stratification in black and white men with benign prostate biopsy.
Kryvenko ON; Wang Y; Sadasivan S; Gupta NS; Rogers C; Bobbitt K; Chitale DA; Rundle A; Tang D; Rybicki BA
Prostate; 2019 Jul; 79(10):1090-1098. PubMed ID: 31045267
[TBL] [Abstract][Full Text] [Related]
17. Essential role for activation of the Polycomb group (PcG) protein chromatin silencing pathway in metastatic prostate cancer.
Berezovska OP; Glinskii AB; Yang Z; Li XM; Hoffman RM; Glinsky GV
Cell Cycle; 2006 Aug; 5(16):1886-901. PubMed ID: 16963837
[TBL] [Abstract][Full Text] [Related]
18. PSA response to finasteride challenge in men with a serum PSA greater than 4 ng/ml and previous negative prostate biopsy: preliminary study.
Kaplan SA; Ghafar MA; Volpe MA; Lam JS; Fromer D; Te AE
Urology; 2002 Sep; 60(3):464-8. PubMed ID: 12350485
[TBL] [Abstract][Full Text] [Related]
19. Racial differences in serum prostate-specific antigen (PSA) doubling time, histopathological variables and long-term PSA recurrence between African-American and white American men undergoing radical prostatectomy for clinically localized prostate cancer.
Tewari A; Horninger W; Badani KK; Hasan M; Coon S; Crawford ED; Gamito EJ; Wei J; Taub D; Montie J; Porter C; Divine GW; Bartsch G; Menon M
BJU Int; 2005 Jul; 96(1):29-33. PubMed ID: 15963115
[TBL] [Abstract][Full Text] [Related]
20. Insulin-like growth factor I (IGF-I) and IGF-binding protein-3 in benign prostatic hyperplasia and prostate cancer.
Khosravi J; Diamandi A; Mistry J; Scorilas A
J Clin Endocrinol Metab; 2001 Feb; 86(2):694-9. PubMed ID: 11158033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
